Table 1 The seven biomarker discovery projects funded by NCI by targeting glycans (information source: http://www.nih.gov/news/pr/aug2007/nci-21.htm)
Project title | Objectives of project |
|---|---|
Discovery and clinical validation of cancer biomarkers using printed glycan array | Determine the diagnostic or prognostic anti-glycan autoantibody signatures in patients. For breast cancer, determine how many years before diagnosis that progression to cancer can be predicted |
Immunogenic sugar moieties of prostate cancers | Identify anti-glycan autoantibody signatures in prostate cancer patients |
Early cancer detection and prognosis through glycomics | Identify biomarkers from glycans released from serum glycoproteins and develop high-throughput platforms to measure biomarkers suitable for the clinic |
Glycan markers for the early detection of breast cancer | Identify breast cancer biomarkers based on aberrant glycan modifications on defined amino acid residues of serum glycoproteins |
Tumor glycomics laboratory for discovery of pancreatic cancer markers | Identify glycoprotein and glycolipid biomarkers for pancreatic cancer in pancreatic ductal fluid that can also be found in serum. Develop assays for promising biomarkers |
Autoantibodies against glycopeptide epitopes as serum biomarkers of cancer | Determine autoantibody signatures to mucin glycopeptides in pancreatic and breast cancer patients |
Neu5Gc and anti-Neu5Gc antibodies for detection of cancer and cancer risk | Expand on research showing that cancer patients express cell surface glycans containing the sialic acid N-glycolylneuraminic Acid (Neu5Gc) and produce autoantibodies to these structures |